Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C

Table 4

Comparison of PTX3 with other indicators for the diagnosis of significant fibrosis (F≥2) by areas under the receiver operating curves (ROC).

	Cut-off; values	AUC (95%CI)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	P value
PTX3 (ng/mL)	4.48	0.802; (0.727-0.877)	73.0	75.5	84.4	60.7	Reference
TGF-β1 (ng/mL)	5.77	0.943; (0.902-0.983)	91.0	98.0	98.8	85.7	< 0.01
HA (ng/mL)	69.37	0.891; (0.829-0.953)	100	73.5	87.3	100	> 0.05
APRI index	0.63	0.831; (0.756-0.906)	80.9	77.6	86.7	69.1	> 0.05
FIB‐4 score	1.86	0.770; (0.690 – 0.851)	77.5	65.3	80.2	61.5	> 0.05
GPR ratio	0.38	0.648; (0.556-0.739)	49.4	89.8	89.8	49.4	< 0.01
LSM (kPa)	8.7	0.904; (0.856-0.953)	76.4	93.9	95.8	68.7	0.02

The optimal cut-off value was calculated from the ROC analysis for PTX3, TGF-β₁, HA, APRI index, FIB‐4 score, and GPR ratio and subsequently the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the markers were calculated. APRI, platelet ratio index; FIB‐4 score; GPR, gamma-glutamyltranspeptidase to platelet ratio; HA, hyaluronic acid; TGF-β₁, transforming growth factor‐β₁.